Fig 1: The platelet proteomic analysis reveals increased HSP90α expression in patients with sepsis. (A) Schematic diagram of the experimental design for DIA‐MS (HD, n = 3; sepsis, n = 3). Volcano plot with significantly increased (red) and decreased (blue) expression of proteins from the HD and sepsis groups. Cutoff: fold change > 1.5 and P value < 0.05. (B) Volcano plot showing significantly increased (red) and decreased (blue) expression of proteins in the HD and severe sepsis groups from OMIX001255. Cutoff: fold change > 2 and P value < 0.05. (C) Venn diagram showing overlap in increased protein expression between our data and OMIX001255. (D) The fold change of HSP90α, FKBP5 and EEF1A1 in HD and sepsis groups. (E) Representative flow cytometry histograms and quantification for HSP90α in platelets from HD (n = 6) and sepsis patients (n = 6). (F) Representative immunofluorescence microscopy of HSP90α (red) and CD41 (green) was performed in platelets from HD and sepsis patients. Scale bar: 10 µm. Relative HSP90α fluorescence intensity was quantified by Image J. (G) Immunoblot and quantification analysis for HSP90α in platelets from HD (n = 3) and sepsis patients (n = 3). (H) Violin plots with HSP90AA1 expression (FPKM) in platelets of HD and sepsis patients from the publicly RNA‐seq data (PRJNA521077). (I) HSP90α mRNA was quantified in platelets from HD (n = 6) and sepsis patients (n = 6). All data are presented as the mean ± SD. Statistical analysis was conducted using unpaired two‐tailed t‐test (E–G, I). * P < 0.05, ** P < 0.01. Each data point represents one human platelet sample (E, F, G, I).